Equities Analysts Offer Predictions for DMRA Q3 Earnings

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) – Stock analysts at HC Wainwright cut their Q3 2026 EPS estimates for Damora Therapeutics, Inc. Common Stock in a report released on Tuesday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.37) per share for the quarter, down from their previous estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock’s current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock’s Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.67) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.59) EPS.

DMRA has been the topic of a number of other reports. TD Cowen assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, June 8th. They issued a “buy” rating on the stock. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Wedbush increased their price objective on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Damora Therapeutics, Inc. Common Stock Trading Up 2.1%

NASDAQ DMRA opened at $31.00 on Thursday. The company has a fifty day simple moving average of $26.88 and a 200 day simple moving average of $26.32. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.45 and a 12-month high of $38.33. The company has a market cap of $1.91 billion, a P/E ratio of -5.56 and a beta of 1.47.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.06.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP bought a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter worth about $76,000. Virtu Financial LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $49,000. Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the third quarter valued at $100,000. Sigma Planning Corp purchased a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $334,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at $266,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.